Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (5517)	5/19/2009 6:46:52 PM
From: RockyBalboa	Respond to of 6370

This stock is awful, and the trading outright manip. The day before, or even hours before it squeezed like mad a well organised pump. Alas,... It looks like a huge "vig", after all. Did you say that crime doesn´t pay? From what I see every day, at least in the short term it pays; can´t tell about the long run other than we are all dead.

To: Kevin Podsiadlik who wrote (5517)	5/19/2009 6:55:11 PM
From: RockyBalboa	Read Replies (1) \| Respond to of 6370

RR is pretty busy doing small cap stock offerings: another one is Pluristem: Pluristem Therapeutics Announces $1.3 Million Securities Offering with Two Institutional Investors NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today it has entered into definitive agreements to sell common stock and warrants to selected institutional investors for aggregate gross proceeds of $1.3 million. The offering is made pursuant to the Form S-3 shelf registration statement that was filed by Pluristem with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on July 1, 2008. The offering is expected to close on or about May 11, 2009, subject to the satisfaction of customary closing conditions. Or also: SEATTLE, April 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that it has agreed to sell up to $20 million of Series 1 Preferred Stock and warrants in a registered offering to a single institutional investor. The investor initially purchased today, for $15 million cash, shares of Series 1 Preferred Stock with a stated value of $15 million and certain associated common stock warrants and has the right to, within 60 days, purchase for an additional $5 million cash additional shares of Series 1 Preferred Stock with a stated value of $5 million with no additional warrants. The Series 1 Preferred Stock is convertible into shares of common stock at a conversion price of $0.30. The investor received 45% warrant coverage on the initial $15 million purchase. The warrants have an exercise price of $0.41 per share, for total potential additional proceeds of approximately $9 million. Approximately three-fifths of the warrants cannot be exercised until after six months from issuance, or 61 days from issuance if the investor does not exercise its option to purchase the additional Series 1 Preferred Stock. The Series 1 Preferred Stock is non-dividend bearing and has no voting rights except to the extent required by law. Separately, the Company reacquired the remaining 100 outstanding shares ($100,000 stated value) of its Series A 3% Convertible Preferred Stock in exchange for 288,517 shares of common stock, and the Company has agreed to reacquire the remaining 1,000 outstanding shares ($1,000,000 stated value) of its Series D 7% Preferred Stock in exchange for shares of common stock based on a formula keyed to the volume-weighted average price over a 3-day period following April 13, 2009. Upon completion of these exchanges, the only preferred stock of the Company outstanding will be the new Series 1 Preferred Stock, thereby relieving the Company of future potential redemptions and restrictive covenants contained in the prior series of Preferred Stock. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM - News), acted as the exclusive placement agent for the transaction.

To: Kevin Podsiadlik who wrote (5517)	5/22/2009 12:57:44 PM
From: RockyBalboa	Read Replies (1) \| Respond to of 6370

HEB has quietly filed a proxy to increase auth shares to 350Mil, from 200Mil (as if they weren´t enough to cover the placement with currently 85M out) Of course the tourists didn´t notice so they still try to buy the dip. It is dated May 26th - we aren´t there yet. Perhaps it slipped out early -g-. We are possibly on the other side of the vig. below, 1.40.. >>>>> HEMISPHERX BIOPHARMA, INC. 1617 JFK Boulevard Philadelphia, Pennsylvania 19103 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 24, 2009 To the Stockholders of Hemispherx Biopharma, Inc.: You are cordially invited to attend the Annual Meeting of Stockholders of Hemispherx Biopharma, Inc. (“Hemispherx”), a Delaware corporation, to be held at the Embassy Suites Hotel, 1776 Benjamin Franklin Parkway, Philadelphia Pennsylvania 19103, on Wednesday, June 24, 2009, at 10:00 a.m. local time, for the following purposes: 1. To elect five members to the Board of Directors of Hemispherx to serve until their respective successors are elected and qualified; 2. To ratify the selection by Hemispherx’s audit committee of McGladrey & Pullen, LLP, independent registered public accountants, to audit the financial statements of Hemispherx for the year ending December 31, 2009; 3. To amend Hemispherx’s certificate of incorporation to increase the number of authorized shares of Hemispherx common stock from 200,000,000 to 350,000,000; 4. To adopt the Hemispherx 2009 Equity Incentive Plan; and 5. To transact such other matters as may properly come before the meeting or any adjournment thereof. Only stockholders of record at the close of business on May 8, 2009 are entitled to notice of and to vote at the meeting. A proxy statement and proxy are enclosed. If you are unable to attend the meeting in person you are urged to sign, date and return the enclosed proxy promptly in the self addressed stamped envelope provided. If you attend the meeting in person, you may withdraw your proxy and vote your shares. We have also enclosed our annual report for the fiscal year ended December 31, 2008. By Order of the Board of Directors \s\ Thomas K. Equels, Secretary Philadelphia, Pennsylvania May 26, 2009 <<<<<<<<<<<<<<<<